242 Phase I study of irinotecan (I), raltitrexed (R), and 5-fluorouracil (5FU) in the treatment of metastatic colorectal cancer (MCRC) refractory to thymidylate synthase inhibitors (TSI)

R.Goel; J.Maroun; C.Cripps; D.Jonker; G.Chiritescu; S.Dahrouge; L.Douglas

首页> 外文期刊>European Journal of Cancer Supplements >242 Phase I study of irinotecan (I), raltitrexed (R), and 5-fluorouracil (5FU) in the treatment of metastatic colorectal cancer (MCRC) refractory to thymidylate synthase inhibitors (TSI)

【24h】

242 Phase I study of irinotecan (I), raltitrexed (R), and 5-fluorouracil (5FU) in the treatment of metastatic colorectal cancer (MCRC) refractory to thymidylate synthase inhibitors (TSI)

机译：242伊立替康（I），雷替曲塞（R）和5-氟尿嘧啶（5FU）用于治疗对胸苷酸合成酶抑制剂（TSI）耐药的转移性结直肠癌（MCRC）的I期研究

获取原文

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

团队文献服务 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《European Journal of Cancer Supplements 》 |2003年第5期| 共1页
作者
R.Goel; J.Maroun; C.Cripps; D.Jonker; G.Chiritescu; S.Dahrouge; L.Douglas;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类肿瘤学 ;
关键词

相似文献

外文文献
中文文献
专利

1. Randomised phase-II trial of CAPIRI (capecitabine, irinotecan) plus bevacizumab vs FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) plus bevacizumab as first-line treatment of patients with unresectable|[sol]|metastatic colorectal cancer (mCRC) [J] . J Souglakos, N Ziras, S Kakolyris, British Journal of Cancer . 2012 ,第3期

机译：CAPIRI（卡培他滨，伊立替康）加贝伐单抗与FOLFIRI（亚叶酸，5-氟尿嘧啶，伊立替康）加贝伐单抗的II期随机试验作为一线治疗不可切除的结肠癌（mCRC）患者
2. A phase II trial of farnesyl protein transferase inhibitor SCH 66336, given by twice-daily oral administration, in patients with metastatic colorectal cancer refractory to 5-fluorouracil and irinotecan. [J] . Sharma S, Kemeny N, Kelsen DP, Annals of oncology: official journal of the European Society for Medical Oncology . 2002 ,第7期

机译：法尼基蛋白转移酶抑制剂SCH 66336的II期临床试验，每天两次口服，用于5-氟尿嘧啶和伊立替康难以治疗的转移性结直肠癌患者。
3. First-line treatment with irinotecan and raltitrexed in metastatic colorectal cancer. Mature results of a multicenter phase II study. [J] . Aparicio J, Vicent JM, Maestu I, Oncology: International Journal of Cancer Research and Treatment . 2005 ,第1期

机译：伊立替康和雷地曲塞治疗转移性大肠癌的一线治疗。多中心II期研究的成熟结果。
4. Randomised phase-II trial of CAPIRI (capecitabine irinotecan) plus bevacizumab vs FOLFIRI (folinic acid 5-fluorouracil irinotecan) plus bevacizumab as first-line treatment of patients with unresectable/metastatic colorectal cancer (mCRC) [O] . J Souglakos, N Ziras, S Kakolyris, 2012

机译：CAPIRI（卡培他滨伊立替康）加贝伐单抗与FOLFIRI（亚叶酸5-氟尿嘧啶伊立替康）加贝伐单抗的II期随机试验作为不可切除/转移性结直肠癌（mCRC）患者的一线治疗
5. Adding Ramucirumab To Second-Line Irinotecan, 5-Fluorouracil and Folinic Acid (Folfiri) Treatment for Metastatic Colorectal Carcinoma (Mcrc): Resource Utilization Data from Raise, A Global, Randomized, Double-Blind, Multicenter Phase 3 Study [O] . P Brück, J Kisro, AL Cohn, 2017

机译：将Ramucirumab添加到二线伊替替康，5-氟尿嘧啶和叶蛋白（Folfiri）治疗用于转移结直肠癌（MCRC）：资源利用数据来自提高，全球，随机，双盲，多中心第3期研究

242 Phase I study of irinotecan (I), raltitrexed (R), and 5-fluorouracil (5FU) in the treatment of metastatic colorectal cancer (MCRC) refractory to thymidylate synthase inhibitors (TSI)

著录项

相似文献

相关主题

期刊订阅